REOLYSIN® is a proprietary variant of the reovirus, a shortened form for Respiratory Enteric Orphan Virus. Reovirus is a naturally occurring virus that is widely hosted and typically affects the gastrointestinal system or respiratory tract, although usually without producing any symptoms. REOLYSIN is being developed as a first-in-class systemically administered immuno-oncology viral agent for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. REOLYSIN is safe and well tolerated with more than 1,000 patients treated to date, with no maximum tolerated dose reached and generally only mild or transient toxicities observed.
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More